Skip to main content
Smart Investors Daily
LM

NASDAQ · LMAT

LeMaitre Vascular, Inc.

Healthcare · Medical - Instruments & Supplies

$80.24

Up+$0.29 (+0.37%)

Updated Sep 16, 2026, 3:45 PM

SID Score

4.1/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
1.89B
P/E ratio
35.4
Dividend yield
1.00%
52-week range
$78.27 – $118.01
Volume
303.22K
Avg. volume
168.66K

Price performance

LMAT price history

1M range · 0 trading sessions · Daily adjusted prices

LMAT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest LMAT news

The latest Smart Investors Daily articles mentioning LMAT.

LMAT research

Overview

Company profile and research snapshot.

Company profile

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$101.50
Implied upside
Analysts
LMAT recent ratings
DateFirmRatingTarget
Aug 5, 2026Wells FargoEqual-Weight
Jun 3, 2026Barrington ResearchOutperform
May 6, 2026CitizensMarket Outperform
May 6, 2026Barrington ResearchOutperform
May 6, 2026Wells FargoEqual-Weight
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

3 Out-of-Favor Stocks with Questionable Fundamentals

The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.

Yahoo · Sep 1, 2026

Speculative Rally Weighed on LeMaitre Vascular (LMAT)

Riverwater Partners, an investment management company, released its ‘Small Cap Strategy’ Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined […]

Yahoo · Aug 27, 2026

LeMaitre to Participate at Upcoming Investor Conferences in September

BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences. Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026, in BostonDorian LeBlanc, CFO, will participate in a Fireside Chat at 8:45 AM ET Morgan Stanley 24th Annual Global Healthcare Conference Wednesday, September 16, 2026, in New York CityDorian LeBlanc, CFO, will participate in a Fireside Chat at 12:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.